Immunic Bolsters Vidofludimus Patent Portfolio in Europe
Event summary
- Immunic received a key European patent (EP3713554) covering dosing regimens for its lead asset, vidofludimus calcium (IMU-838).
- The patent, granted by the EPO, is expected to provide protection in Europe until at least 2038, with potential extension to 2043 via a Supplementary Protection Certificate (SPC).
- A corresponding patent was previously granted by the USPTO in 2023.
- The patent broadly covers all forms of vidofludimus, including salts, solvates, and the free acid, across all label-relevant dosing regimens.
- Immunic’s existing patent portfolio, including composition-of-matter, indication, and method-of-treatment patents, is expected to provide protection into 2041 in the US and up to 2045 with pending applications.
The big picture
The patent grant strengthens Immunic’s position in the crowded multiple sclerosis treatment market, where intellectual property protection is paramount. Securing broad patent coverage, especially in key markets like Europe, is crucial for recouping the substantial R&D investments required for novel therapies. The company's layered IP strategy aims to create a durable competitive advantage, but ongoing vigilance against design-around attempts will be essential.
What we're watching
- SPC Approval
- The approval of a Supplementary Protection Certificate will be critical in extending Immunic's market exclusivity in Europe beyond 2038, and the timeline for this decision warrants close monitoring.
- Design-Around Risk
- Competitors may attempt to design around the patent's scope, particularly concerning alternative formulations or dosing strategies, which could erode Immunic's exclusivity.
- Clinical Trial Impact
- The strength of Immunic’s patent position will influence the commercial viability of vidofludimus calcium, and the success of ongoing phase 3 trials will be a key determinant of its long-term value.
Related topics